Investigators are presenting more than 380 abstracts on preliminary findings in the diagnosis and treatment of allergic diseases at the ACAAI Annual Meeting in Philadelphia, Nov. 9-15. Following are highlights of some key investigations on anaphylaxis, food allergy and insect allergy.
Investigators are presenting more than 380 abstracts on preliminary findings in the diagnosis and treatment of allergic diseases at the ACAAI Annual Meeting in Philadelphia, Nov. 9-15. Following are highlights of some key investigations on allergic asthma.
Scientists at Children?s Hospital of Pittsburgh of UPMC have identified a protein that is critical to the development of inflammation during lung infection in patients with cystic fibrosis (CF). The identification of this protein, called interleukin-23 (IL-23), is an important finding that gives researchers a specific target for developing new therapies.
Results of a Portuguese study suggest that, contrary to expectations, obesity is not associated with an increased risk of asthma.
A Colorado-based company is launching a line of ‘medical- food’ products for the dietary management of asthma, eczema and other allergic conditions based on discoveries by Floyd H. ‘Ski’ Chilton, Ph.D., of Wake Forest University Health Sciences (WFUHS).
Scientists at Children’s Hospital of Pittsburgh of UPMC have identified a protein that is critical to the development of inflammation during lung infection in patients with cystic fibrosis. The identification of this protein, called interleukin-23, is an important finding that gives researchers a specific target for developing new therapies.
Researchers who thought they had identified the bacterial perpetrator of the often severe disease caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) had better keep looking: Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have exonerated a toxin widely thought to be the guilty party.
By combining four proteins of Staphylococcus aureus that individually generated the strongest immune response in mice, scientists have created a vaccine that significantly protects the animals from diverse strains of the bacterium that cause disease in humans. A report describing the University of Chicago study, funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, appears online this week in the Proceedings of the National Academy of Sciences.
New data presented today show patients taking pramipexole (Mirapexin?/ Sifrol?) can experience significant improvements in a broad range of symptoms associated with Restless Legs Syndrome (RLS).1 In an additional study presented today, pramipexole was also shown to be well tolerated in RLS patients affected by concomitant diseases, which are commonly experienced in this patient group.2 The results of the studies were presented at the 10th International Congress of Parkinson?s Disease and Movement Disorders (MDS) in Kyoto, Japan.
Harvard School of Public Health (HSPH) has awarded its highest honor, for the promotion of high public health standards among vulnerable populations, to William H. Foege, former Director of the U.S. Centers for Disease Control and a founder of the Task Force for Child Survival and Development, and Anthony S. Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID). The two recipients have dedicated their lives to protecting people in this country and throughout the world from infectious diseases.